TRDA Q3 2024 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M-55.3% YoY

Gross Profit

$20M100.0% margin

Operating Income

-$22M-110.7% margin

Net Income

-$14M-71.7% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

-79.3%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$555M

Total Liabilities

$132M

Stockholders' Equity

$422M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$44M	-55.3%
Gross Profit	$20M	$22M	-9.2%
Operating Income	-$22M	$14M	-254.6%
Net Income	-$14M	$35M	-139.6%

Revenue Segments

License

$54M100%